The microenvironment, or niche, in which hematopoietic stem cells (HSC) reside, is essential for their regulation. Since HSC number limits their clinical use, strategies to increase HSC through niche manipulation could increase the scope of their therapeutic application. The long-term objective of this proposal is to manipulate the bone marrow microenvironment to increase HSC numbers and thereby their clinical utility. To meet this objective, we established a novel experimental model in which treatment with parathyroid hormone (PTH) and/or activation of its receptor (PTH1R) in osteoblastic cells expands Long-term HSC (LT-HSC), thus identifying osteoblastic cells as key regulators of HSC. While defining mediators of PTH action in the niche, we discovered that Prostaglandin E2 (PGE2), which is released by osteoblastic cells upon PTH treatment, selectively expands Short-term HSC (ST-HSC) in vivo. Such exquisite and specialized regulation of HSC subsets has not previously been achieved, but we believe that it will have important therapeutic implications. Therefore, we have developed two unique experimental tools to define HSC regulation. Based on our observations, we hypothesize that independent mechanisms selectively regulate LT-HSC and ST-HSC and that these have different effects on HSC regulation. To demonstrate this hypothesis, this proposal will pursue three specific aims.
In Aim1, the specific cellular and molecular mechanisms that mediate LT-HSC expansion in response to PTH will be defined in vivo by pharmacologic and genetic means.
In Aim2, the specific cellular and molecular mechanisms that mediate PGE2-dependent ST-HSC expansion will be defined in vivo and in vitro.
In Aim 3, interactions between regulation of LT-HSC and ST-HSC will be established. Data from the studies proposed in this application will 1) define the PTH and PGE2-activated mechanisms regulating LT-HSC and ST-HSC;2) identify interactions between these mechanisms which could be exploited for targeted regulation of HSC subsets in the setting of specific therapeutic need. The studies proposed are therefore designed to result in findings that not only advance the understanding of stem cell regulation, but also devise pharmacologic strategies that can be brought back to patients, directly impacting their clinical care. The availability of PTH and PGE2 receptor specific agonists makes these studies particularly timely for future translation to human therapy. Using two novel in vivo experimental tools, this project will determine specific regulatory mechanisms, direct and indirect, that control HSC behavior, and that can stimulate differentially subsets of HSC which have different properties. Since HSC give rise to all blood cells, these regulatory mechanisms could be therapeutically exploited to increase HSC in specific situations of blood cell injury or deficiency.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK076876-03
Application #
7802248
Study Section
Hematopoiesis Study Section (HP)
Program Officer
Wright, Daniel G
Project Start
2008-05-01
Project End
2013-04-30
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
3
Fiscal Year
2010
Total Cost
$304,920
Indirect Cost
Name
University of Rochester
Department
Internal Medicine/Medicine
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Evans, Andrew G; Calvi, Laura M (2015) Notch signaling in the malignant bone marrow microenvironment: implications for a niche-based model of oncogenesis. Ann N Y Acad Sci 1335:63-77
Calvi, Laura M; Link, Daniel C (2014) Cellular complexity of the bone marrow hematopoietic stem cell niche. Calcif Tissue Int 94:112-24
Frisch, Benjamin J; Calvi, Laura M (2014) Hematopoietic stem cell cultures and assays. Methods Mol Biol 1130:315-324
Porter, Rebecca L; Georger, Mary A; Bromberg, Olga et al. (2013) Prostaglandin E2 increases hematopoietic stem cell survival and accelerates hematopoietic recovery after radiation injury. Stem Cells 31:372-83
Dhillon, Robinder S; Xie, Chao; Tyler, Wakenda et al. (2013) PTH-enhanced structural allograft healing is associated with decreased angiopoietin-2-mediated arteriogenesis, mast cell accumulation, and fibrosis. J Bone Miner Res 28:586-97
Smith, Julianne N P; Calvi, Laura M (2013) Concise review: Current concepts in bone marrow microenvironmental regulation of hematopoietic stem and progenitor cells. Stem Cells 31:1044-50
Frisch, Benjamin J; Ashton, John M; Xing, Lianping et al. (2012) Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia. Blood 119:540-50
Bromberg, Olga; Frisch, Benjamin J; Weber, Jonathan M et al. (2012) Osteoblastic N-cadherin is not required for microenvironmental support and regulation of hematopoietic stem and progenitor cells. Blood 120:303-13
Calvi, Laura M; Bromberg, Olga; Rhee, Yumie et al. (2012) Osteoblastic expansion induced by parathyroid hormone receptor signaling in murine osteocytes is not sufficient to increase hematopoietic stem cells. Blood 119:2489-99
Smith, Julianne N; Calvi, Laura M (2011) Regulatory Interactions in the Bone Marrow Microenvironment. IBMS Bonekey 8:96-111

Showing the most recent 10 out of 17 publications